Myelopid & MP-1–MP-6Миелопид / миелопептиды
What is it?
A marrow-peptide family separating the original mixture from defined isolates and later synthetic research. Each member needs its own evidence.
Research context
A marrow-peptide family separating the original mixture from defined isolates and later synthetic research. Each member needs its own evidence.
What the studies found
in vitro · 2000
Human leukemia cell lines; porcine marrow-derived peptide
MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.
Limit: Preclinical findings do not establish human benefit or safety.
A new endogenous differentiating factor (myelopeptide-4) for myeloid cells. ↗in vitro · 2005
HL-60, K-562 and THP-1 cell lines
MP-4 increased differentiation-associated antigens and mature-cell features in leukemia cell cultures, with phagocytosis also examined. The report extends laboratory characterization rather than demonstrating clinical efficacy.
Limit: Preclinical findings do not establish human benefit or safety.
Induction of differentiation in leukemic cell strains with myelopeptide-4. ↗in vitro · 2006
Human T-cell cultures exposed to tumor-conditioned medium or measles virus
MP-2 (LVVYPW) restored IL-2 production and receptor expression in experimentally suppressed human T cells. Human-derived cells do not make this a human treatment trial.
Limit: Preclinical findings do not establish human benefit or safety.
Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus. ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Peptide research family
- Research collection
- Peptide bioregulation · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human treatment trial assessed for this family
- Study methods
- —Member-specific studies; patents and archival leads identified separately
- Independent replication
- —Independent replication not established by the records collected here
- Source access
- —Primary abstracts, selected full texts, patents and explicit retrieval targets
- Safety evidence
- —Cell and animal effects do not establish human safety; analogues may differ
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Inside this research family
Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.
| Member | Identity | What the source supports |
|---|---|---|
| MP-1 | FLGFPT; historical identification lead | Original isolation and functional source recovery pending. Original-source recovery pending |
| MP-2 | LVVYPW | T-cell IL-2 studies and mouse tumor experiments; Bivalen formulation equivalence needs separate verification. Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice. ↗ |
| MP-3 | LVCYPQ | Patent isolate; a Seramil name/sequence link remains to be independently resolved. |
| MP-4 | FRPRIMTP | Original FEBS publication supports this octapeptide and cell differentiation findings. A new endogenous differentiating factor (myelopeptide-4) for myeloid cells. ↗ Induction of differentiation in leukemic cell strains with myelopeptide-4. ↗ |
| MP-5 / MP-6 | VVYPD / VDPP | Patent-defined isolates with distinct experimental profiles, not interchangeable immune stimulants. |
| Myelopid mixture | Multiple marrow-derived components | Opioid-related and antibody-stimulating fractions separated chromatographically. Participation by opioids in the immunostimulatory activity of myelopeptides. ↗ |
Interpretation and open questions
The hemoglobin/hemorphin connection is a sequence-lineage research lead. It does not make every MP peptide an opioid agonist.
Spinorphin and tynorphin are adjacent hemoglobin-fragment programs, not synonyms for MP-2. A later recombinant precursor and conflicting MP-4 transcriptions require separate source review.
Petrov, Mikhailova, Fonina and Stepanenko’s Myelopeptides monograph (Nauka, 2001; ISBN 5-02-006503-X) remains a full-text acquisition target.
Linked sources
Explore the research map and unresolved leads ↗
A new endogenous differentiating factor (myelopeptide-4) for myeloid cells.
Strelkov LA, Mikhailova AA, Fonina LA, Petrov RV · FEBS letters
MP-4 (FRPRIMTP), isolated from porcine marrow culture, altered differentiation markers and morphology in HL-60 and K-562 leukemia cell lines. This was not a leukemia treatment trial.
- Population / setting
- Human leukemia cell lines; porcine marrow-derived peptide
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Induction of differentiation in leukemic cell strains with myelopeptide-4.
Kirilina EA, Suvorov NI, Popova SS, Khaidukov SV, Rapoport EM, Fonina LA, Mikhailova AA · Bulletin of experimental biology and medicine
MP-4 increased differentiation-associated antigens and mature-cell features in leukemia cell cultures, with phagocytosis also examined. The report extends laboratory characterization rather than demonstrating clinical efficacy.
- Population / setting
- HL-60, K-562 and THP-1 cell lines
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus.
Mikhailova AA, Belevskaya RG, Kalyuzhnaya M, Fonina LA, Liashenko VA, Petrov RV · Journal of immunotherapy (Hagerstown, Md. : 1997)
MP-2 (LVVYPW) restored IL-2 production and receptor expression in experimentally suppressed human T cells. Human-derived cells do not make this a human treatment trial.
- Population / setting
- Human T-cell cultures exposed to tumor-conditioned medium or measles virus
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Effect of myelopeptide-2 on the development of spontaneous and urethane-induced tumors in mice.
Mikhailova AA, Kirilina EA, Morozova OV, Turusov VS · Bulletin of experimental biology and medicine
MP-2 altered the appearance and number of spontaneous and urethane-induced lung tumors in mice. Laboratory tumor outcomes do not establish cancer prevention or treatment in people.
- Population / setting
- Mice; spontaneous and carcinogen-induced tumors
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Participation by opioids in the immunostimulatory activity of myelopeptides.
Zakharova LA, Belevskaya RG, Yanovskii OG · Biomedical science
Antibody-stimulating material and beta-endorphin eluted in different chromatographic fractions. The original mixture’s opioid-related effects cannot be assigned to every defined MP-1–MP-6 peptide.
- Population / setting
- Mice, marrow peptide fractions and chromatography
- What was checked
- Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Limitations & review scope
- Preclinical findings do not establish human benefit or safety.
- Indexed abstract reviewed; full methods and independent replication require appraisal.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.
Myelopeptides and their therapeutic use — US6469137B1
· Primary source linked above
MP-3, MP-4, MP-5 and MP-6 were described as marrow-culture isolates with nonuniform immune, differentiation and antiviral assay results. The patent does not establish that the mixture or every member shares these activities.
- Population / setting
- Cell assays and mouse experiments
- What was checked
- Selected original-source text checked; full methodological review pending.
Limitations & review scope
- Patent efficacy proposals are not clinical evidence.
- Commercial product names require formulation-specific confirmation.
Source checked 2026-10-05. This is a source-linked record, not a completed evidence review.